Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+T cells

Li Xin Wang, Wen Xin Huang, Hallie Graor, Peter A Cohen, Julian A. Kim, Suyu Shu, Gregory E. Plautz

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

T cell-mediated cancer immunotherapy is dose dependent and optimally requires participation of antigen-specific CD4+ and CD8+ T cells. Here, we isolated tumor-sensitized T cells and activated them in vitro using conditions that led to greater than 108-fold numerical hyperexpansion of either the CD4+ or CD8+ subset while retaining their capacity for in vivo therapeutic efficacy. Murine tumor-draining lymph node (TDLN) cells were segregated to purify the CD62Llow subset, or the CD4+ subset thereof. Cells were then propagated through multiple cycles of anti-CD3 activation with IL-2 + IL-7 for the CD8+ subset, or IL-7 + IL-23 for the CD4+ subset. A broad repertoire of TCR Vβ families was maintained throughout hyperexpansion, which was similar to the starting population. Adoptive transfer of hyper-expanded CD8+ T cells eliminated established pulmonary metastases, in an immunologically specific fashion without the requirement for adjunct IL-2. Hyperexpanded CD4+ T cells cured established tumors in intracranial or subcutaneous sites that were not susceptible to CD8+ T cells alone. Because accessibility and antigen presentation within metastases varies according to anatomic site, maintenance of a broad repertoire of both CD4+ and CD8+ T effector cells will augment the overall systemic efficacy of adoptive immunotherapy.

Original languageEnglish (US)
JournalJournal of Translational Medicine
Volume2
DOIs
StatePublished - Nov 26 2004
Externally publishedYes

Fingerprint

Adoptive Immunotherapy
T-cells
T-Lymphocytes
Tumors
Interleukin-7
Neoplasms
Interleukin-2
Neoplasm Metastasis
CD8 Antigens
Interleukin-23
Antigens
CD4 Antigens
Adoptive Transfer
Antigen Presentation
Immunotherapy
Lymph Nodes
Chemical activation
Maintenance
Lung
Population

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+T cells. / Wang, Li Xin; Huang, Wen Xin; Graor, Hallie; Cohen, Peter A; Kim, Julian A.; Shu, Suyu; Plautz, Gregory E.

In: Journal of Translational Medicine, Vol. 2, 26.11.2004.

Research output: Contribution to journalArticle

Wang, Li Xin ; Huang, Wen Xin ; Graor, Hallie ; Cohen, Peter A ; Kim, Julian A. ; Shu, Suyu ; Plautz, Gregory E. / Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+T cells. In: Journal of Translational Medicine. 2004 ; Vol. 2.
@article{186761f49ce94987bafa3512e8230a7b,
title = "Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+T cells",
abstract = "T cell-mediated cancer immunotherapy is dose dependent and optimally requires participation of antigen-specific CD4+ and CD8+ T cells. Here, we isolated tumor-sensitized T cells and activated them in vitro using conditions that led to greater than 108-fold numerical hyperexpansion of either the CD4+ or CD8+ subset while retaining their capacity for in vivo therapeutic efficacy. Murine tumor-draining lymph node (TDLN) cells were segregated to purify the CD62Llow subset, or the CD4+ subset thereof. Cells were then propagated through multiple cycles of anti-CD3 activation with IL-2 + IL-7 for the CD8+ subset, or IL-7 + IL-23 for the CD4+ subset. A broad repertoire of TCR Vβ families was maintained throughout hyperexpansion, which was similar to the starting population. Adoptive transfer of hyper-expanded CD8+ T cells eliminated established pulmonary metastases, in an immunologically specific fashion without the requirement for adjunct IL-2. Hyperexpanded CD4+ T cells cured established tumors in intracranial or subcutaneous sites that were not susceptible to CD8+ T cells alone. Because accessibility and antigen presentation within metastases varies according to anatomic site, maintenance of a broad repertoire of both CD4+ and CD8+ T effector cells will augment the overall systemic efficacy of adoptive immunotherapy.",
author = "Wang, {Li Xin} and Huang, {Wen Xin} and Hallie Graor and Cohen, {Peter A} and Kim, {Julian A.} and Suyu Shu and Plautz, {Gregory E.}",
year = "2004",
month = "11",
day = "26",
doi = "10.1186/1479-5876-2-41",
language = "English (US)",
volume = "2",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+T cells

AU - Wang, Li Xin

AU - Huang, Wen Xin

AU - Graor, Hallie

AU - Cohen, Peter A

AU - Kim, Julian A.

AU - Shu, Suyu

AU - Plautz, Gregory E.

PY - 2004/11/26

Y1 - 2004/11/26

N2 - T cell-mediated cancer immunotherapy is dose dependent and optimally requires participation of antigen-specific CD4+ and CD8+ T cells. Here, we isolated tumor-sensitized T cells and activated them in vitro using conditions that led to greater than 108-fold numerical hyperexpansion of either the CD4+ or CD8+ subset while retaining their capacity for in vivo therapeutic efficacy. Murine tumor-draining lymph node (TDLN) cells were segregated to purify the CD62Llow subset, or the CD4+ subset thereof. Cells were then propagated through multiple cycles of anti-CD3 activation with IL-2 + IL-7 for the CD8+ subset, or IL-7 + IL-23 for the CD4+ subset. A broad repertoire of TCR Vβ families was maintained throughout hyperexpansion, which was similar to the starting population. Adoptive transfer of hyper-expanded CD8+ T cells eliminated established pulmonary metastases, in an immunologically specific fashion without the requirement for adjunct IL-2. Hyperexpanded CD4+ T cells cured established tumors in intracranial or subcutaneous sites that were not susceptible to CD8+ T cells alone. Because accessibility and antigen presentation within metastases varies according to anatomic site, maintenance of a broad repertoire of both CD4+ and CD8+ T effector cells will augment the overall systemic efficacy of adoptive immunotherapy.

AB - T cell-mediated cancer immunotherapy is dose dependent and optimally requires participation of antigen-specific CD4+ and CD8+ T cells. Here, we isolated tumor-sensitized T cells and activated them in vitro using conditions that led to greater than 108-fold numerical hyperexpansion of either the CD4+ or CD8+ subset while retaining their capacity for in vivo therapeutic efficacy. Murine tumor-draining lymph node (TDLN) cells were segregated to purify the CD62Llow subset, or the CD4+ subset thereof. Cells were then propagated through multiple cycles of anti-CD3 activation with IL-2 + IL-7 for the CD8+ subset, or IL-7 + IL-23 for the CD4+ subset. A broad repertoire of TCR Vβ families was maintained throughout hyperexpansion, which was similar to the starting population. Adoptive transfer of hyper-expanded CD8+ T cells eliminated established pulmonary metastases, in an immunologically specific fashion without the requirement for adjunct IL-2. Hyperexpanded CD4+ T cells cured established tumors in intracranial or subcutaneous sites that were not susceptible to CD8+ T cells alone. Because accessibility and antigen presentation within metastases varies according to anatomic site, maintenance of a broad repertoire of both CD4+ and CD8+ T effector cells will augment the overall systemic efficacy of adoptive immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=18144423563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144423563&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-2-41

DO - 10.1186/1479-5876-2-41

M3 - Article

VL - 2

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

ER -